Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 601 to 650 of 2555

TitleReference numberPublishedLast updated
Zanubrutinib for treating Waldenstrom's macroglobulinaemiaTA833
Fostamatinib for treating refractory chronic immune thrombocytopeniaTA835
Pembrolizumab for adjuvant treatment of renal cell carcinomaTA830
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroidsTA832
O2matic PRO 100 for optimising oxygen treatment in respiratory conditionsMIB308
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancerHTG642
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapyTA827
Ozanimod for treating moderately to severely active ulcerative colitisTA828
Signatera for detecting molecular residual disease from solid tumour cancersMIB307
Upadacitinib for treating active ankylosing spondylitisTA829
Postnatal careQS37
Neurostimulation of lumbar muscles for refractory non-specific chronic low back painHTG641
iTind for lower urinary tract symptoms caused by benign prostatic hyperplasiaMIB306
Neuropad for detecting preclinical diabetic peripheral neuropathyHTG486
Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasiaHTG639
Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopauseHTG640
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitisTA825
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)TA826
Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomasCG118
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)TA822
Dexamethasone intravitreal implant for treating diabetic macular oedemaTA824
Self-harm: assessment, management and preventing recurrenceNG225
Self‑harmQS34
Faecal microbiota transplant for recurrent Clostridioides difficile infectionHTG638
Brolucizumab for treating diabetic macular oedemaTA820
Contrast-enhanced spectral mammography for breast cancerMIB304
Differential target multiplexed spinal cord stimulation for chronic lower back and leg painMIB305
iFuse for treating chronic sacroiliac joint painHTG488
Focal resurfacing implants to treat articular cartilage damage in the kneeHTG635
Transcutaneous electrical neuromuscular stimulation for urinary incontinenceHTG636
Superficial venous arterialisation for chronic limb threatening ischaemiaHTG637
Avalglucosidase alfa for treating Pompe diseaseTA821
Type 1 diabetes in adults: diagnosis and managementNG17
Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infectionsAMR1
Cefiderocol for treating severe drug-resistant gram-negative bacterial infectionsAMR2
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesotheliomaTA818
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
SecurAcath for securing percutaneous cathetersHTG440
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
Stockholm3 for prostate cancer screeningMIB303
Bioresorbable stent implantation to treat coronary artery diseaseHTG633
Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissectionHTG634
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitorsTA813
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitisTA814
Urinary tract infection in under 16s: diagnosis and managementNG224
Melanoma: assessment and managementNG14
Fever in under 5sQS64

Results per page

  1. 10
  2. 25
  3. 50
  4. All